TABLE OF CONTENTS
1 INTRODUCTION 31
1.1 OBJECTIVES OF THE STUDY 31
1.2 MARKET DEFINITION 31
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET 31
1.4 CURRENCY AND PRICING 33
1.5 LIMITATIONS 33
1.6 MARKETS COVERED 34
2 MARKET SEGMENTATION 37
2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 DBMR TRIPOD DATA VALIDATION MODEL 40
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 43
2.6 MULTIVARIATE MODELLING 44
2.7 MARKET END USER COVERAGE GRID 45
2.8 SOURCE LIFELINE CURVE 46
2.9 DBMR MARKET POSITION GRID 47
2.10 VENDOR SHARE ANALYSIS 49
2.11 SECONDARY SOURCES 50
2.12 ASSUMPTIONS 50
3 EXECUTIVE SUMMARY 51
4 PREMIUM INSIGHT 54
4.1 PESTEL ANALYSIS 55
4.2 PORTERS FIVE FORCES 56
5 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: REGULATIONS 57
6 MARKET OVERVIEW 62
6.1 DRIVERS 64
6.1.1 RISING INCIDENCE OF HEREDITARY CANCER 64
6.1.2 INCREASE IN THE GERIATRIC POPULATION 64
6.1.3 RISING HEALTHCARE SPENDING 65
6.1.4 INCREASE IN AWARENESS ABOUT CANCER TESTING 65
6.2 RESTRAINTS 66
6.2.1 HIGH COST OF HEREDITARY CANCER TESTING 66
6.2.2 LACK OF SKILLED PROFESSIONALS 67
6.3 OPPORTUNITIES 67
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 67
6.3.2 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS 68
6.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS 69
6.3.4 TECHNOLOGICAL DEVELOPMENTS IN HEREDITARY CANCER TESTING PROCEDURES 69
6.4 CHALLENGES 70
6.4.1 ETHICAL CHALLENGES FACED DURING HEREDITARY CANCER TESTING 70
6.4.2 RISING COMPETITION AMONG MARKET PLAYERS 71
7 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE 72
7.1 OVERVIEW 73
7.2 MULTI PANEL TEST 76
7.3 SINGLE-SITE GENETIC TEST 76
8 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE 77
8.1 OVERVIEW 78
8.2 BIOPSY 81
8.2.1 NEEDLE BIOPSIES 81
8.2.2 ENDOSCOPIC BIOPSIES 81
8.2.3 LAPAROSCOPIC, THORACOSCOPIC, AND MEDIASTINOSCOPIC BIOPSY 82
8.2.4 LAPAROTOMY AND THORACOTOMY 82
8.2.5 OTHERS 82
8.3 IMAGING 82
8.3.1 MAGNETIC RESONANCE IMAGING (MRI) 83
8.3.2 COMPUTED TOMOGRAPHY (CT) SCAN 83
8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 83
8.3.4 NUCLEAR SCAN 83
8.3.5 ULTRASOUND 83
8.3.6 X-RAYS 83
8.4 LAB TESTS 84
8.4.1 BLOOD 84
8.4.2 URINE 84
8.4.3 OTHERS 84
9 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY 85
9.1 OVERVIEW 86
9.2 POLYMERASE CHAIN REACTION (PCR) 89
9.3 SEQUENCING 89
9.4 MICRO ARRAY 90
10 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE 91
10.1 OVERVIEW 92
10.2 HEREDITARY BREAST & OVARIAN CANCER SYNDROME 95
10.3 COWDEN SYNDROME 95
10.4 LYNCH SYNDROME 96
10.5 HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROME 96
10.6 FAMILIAL ADENOMATOUS POLYPOSIS (FAP) 97
10.7 LI-FRAUMENI SYNDROME 97
10.8 VON HIPPEL-LINDAU DISEASE 98
10.9 MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROME 98
11 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY END USER 99
11.1 OVERVIEW 100
11.2 HOSPITALS 103
11.3 CLINICS 103
11.4 DIAGNOSTIC CENTERS 104
11.5 RADIOLOGY CENTERS 104
11.6 LABORATORIES 105
11.7 OTHERS 105
12 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL 106
12.1 OVERVIEW 107
12.2 DIRECT TENDER 110
12.3 RETAIL SALES 110
13 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY REGION 111
13.1 MIDDLE EAST AND AFRICA 112
13.1.1 SOUTH AFRICA 120
13.1.2 SAUDI ARABIA 124
13.1.3 U.A.E. 128
13.1.4 EGYPT 132
13.1.5 ISRAEL 136
13.1.6 REST OF THE MIDDLE EAST AND AFRICA 140
14 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: COMPANY LANDSCAPE 141
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 141
15 SWOT ANALYSIS 142
16 COMPANY PROFILE 143
16.1 ABBOTT 143
16.1.1 COMPANY SNAPSHOT 143
16.1.2 REVENUE ANALYSIS 143
16.1.3 COMPANY SHARE ANALYSIS 144
16.1.4 PRODUCT PORTFOLIO 144
16.1.5 RECENT DEVELOPMENTS 144
16.2 ILLUMINA, INC. (2021) 145
16.2.1 COMPANY SNAPSHOT 145
16.2.2 REVENUE ANALYSIS 145
16.2.3 COMPANY SHARE ANALYSIS 146
16.2.4 PRODUCT PORTFOLIO 146
16.2.5 RECENT DEVELOPMENTS 147
16.3 PERKINELMER INC. (2021) 148
16.3.1 COMPANY SNAPSHOT 148
16.3.2 REVENUE ANALYSIS 148
16.3.3 COMPANY SHARE ANALYSIS 149
16.3.4 PRODUCT PORTFOLIO 149
16.3.5 RECENT DEVELOPMENTS 149
16.4 LIFELABS GENETICS 150
16.4.1 COMPANY SNAPSHOT 150
16.4.2 COMPANY SHARE ANALYSIS 150
16.4.3 PRODUCT PORTFOLIO 151
16.4.4 RECENT DEVELOPMENTS 151
16.5 EUROFINS SCIENTIFIC (2021) 152
16.5.1 COMPANY SNAPSHOT 152
16.5.2 REVENUE ANALYSIS 152
16.5.3 COMPANY SHARE ANALYSIS 153
16.5.4 PRODUCT PORTFOLIO 153
16.5.5 RECENT DEVELOPMENT 153
16.6 AMBRY GENETICS 154
16.6.1 COMPANY SNAPSHOT 154
16.6.2 REVENUE ANALYSIS 154
16.6.3 PRODUCT PORTFOLIO 155
16.6.4 RECENT DEVELOPMENTS 155
16.7 BIOCARTIS 156
16.7.1 COMPANY SNAPSHOT 156
16.7.2 REVENUE ANALYSIS 156
16.7.3 PRODUCT PORTFOLIO 157
16.7.4 RECENT DEVELOPMENTS 157
16.8 BIO-HELIX 158
16.8.1 COMPANY SNAPSHOT 158
16.8.2 PRODUCT PORTFOLIO 158
16.8.3 RECENT DEVELOPMENTS 158
16.9 BIOREFERENCE (A SUBSIDIARY OF OPKO HEALTH, INC.) (2021) 159
16.9.1 COMPANY SNAPSHOT 159
16.9.2 REVENUE ANALYSIS 159
16.9.3 PRODUCT PORTFOLIO 160
16.9.4 RECENT DEVELOPMENT 160
16.10 CENTOGENE N.V. (2021) 161
16.10.1 COMPANY SNAPSHOT 161
16.10.2 REVENUE ANALYSIS 161
16.10.3 PRODUCT PORTFOLIO 162
16.10.4 RECENT DEVELOPMENT 162
16.11 CEPHEID 163
16.11.1 COMPANY SNAPSHOT 163
16.11.2 PRODUCT PORTFOLIO 163
16.11.3 RECENT DEVELOPMENT 163
16.12 FULGENT GENETICS 164
16.12.1 COMPANY SNAPSHOT 164
16.12.2 REVENUE ANALYSIS 164
16.12.3 PRODUCT PORTFOLIO 165
16.12.4 RECENT DEVELOPMENT 165
16.13 INVITAE CORPORATION 166
16.13.1 COMPANY SNAPSHOT 166
16.13.2 REVENUE ANALYSIS 166
16.13.3 PRODUCT PORTFOLIO 167
16.13.4 RECENT DEVELOPMENT 167
16.14 NATERA, INC. (2021) 168
16.14.1 COMPANY SNAPSHOT 168
16.14.2 REVENUE ANALYSIS 168
16.14.3 PRODUCT PORTFOLIO 169
16.14.4 RECENT DEVELOPMENTS 169
16.15 4BASECARE. 171
16.15.1 COMPANY SNAPSHOT 171
16.15.2 PRODUCT PORTFOLIO 171
16.15.3 RECENT DEVELOPMENTS 172
17 QUESTIONNAIRE 173
18 RELATED REPORTS 176

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.